Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22661725 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL918791 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29549533 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL918568 | 1.00 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL30403231 | 0.98 | NPC1 (0.42) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL29001613 | 0.98 | NPC1 (0.42) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL19765232 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL27932371 | 0.88 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12116904 | 0.80 | NPC1 (0.38) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL20500207 | 0.79 | NPC1 (0.40) | NPC1MEN1KMT2AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113004517-B | Modified epoxy resin, adhesive, preparation method and application thereof | 广州市白云化工实业有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-111548329-B | Preparation method of brivaracetam | 浙江乐普药业股份有限公司 | 2022-06-17 | — | — | CN | claimed |
| US-20250155812-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE RESIN FILM, PHOTOSENSITIVE DRY FILM, AND PATTERN-FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-05-15 | — | — | US | disclosed |
| CN-114391030-B | Chemically compatible fluoropolymer blends | 大金美国股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115304568-B | Asymmetric synthesis method of 6-azidomethylene-1-aryl-3-oxabicyclo [3,1,0] hex-2-one | 扬州大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-116102527-B | Preparation method of peach aldehyde | 万华化学集团股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-116102527-A | Preparation method of peach aldehyde | 万华化学集团股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116057105-A | Fluoropolymer and liquid crystal polymer blends | 大金美国股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-113004517-B | Modified epoxy resin, adhesive, preparation method and application thereof | 广州市白云化工实业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-111548329-B | Preparation method of brivaracetam | 浙江乐普药业股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114031573-B | Method for recovering ligand in S- (+) -2, 2-dimethyl cyclopropane formic acid asymmetric synthesis | 深圳市海滨制药有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114391030-A | Chemically compatible fluoropolymer blends | 大金美国股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| EP-3122707-A1 | METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND | Dow Global Technologies LLC (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148931-A1 | METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-1950208-B1 | PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | SUMITOMO CHEMICAL CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-7928253-B2 | Method of producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100168463-A1 | METHOD OF PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1950208-A1 | PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | Sumitomo Chemical Company, Limited (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168463-A1 | METHOD OF PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE | CYP1B1, HACL2, CMA1 | NPC1 2056/4885MEN1 3183/4885KMT2A 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.